XKRX
003850
Market cap541mUSD
Oct 08, Last price
8,610.00KRW
1D
-1.82%
1Q
1.65%
Jan 2017
-6.55%
Name
Boryung Corp
Chart & performance
P/E
11.31
P/S
0.71
EPS
761.16
Div yield, %
1.86%
Shrs. gr., 5y
7.16%
Rev. gr., 5y
12.61%
Revenues
1.02t
+0.03%
Net income
64.30b
-7.65%
CFO
133.18b
+65.32%
Dividend
Dec 29, 2025160 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, South Korea.
Key people
Heung Su Nam
Assistant Managing Director · since 2024
Se Yong Park
Assistant Managing Director
Taek Hwan Shin
Assistant Managing Director · since 2024
Baek Min Sung
Assistant Managing Director
Assistant Managing Director
Jeong Gyun Kim
Chairman of the Board, Chief Executive Officer · since 2025
Tae Jin Cha
Non-Executive Independent Director
Yin Ho Park
Non-Executive Independent Director · since 2024
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||